Rajender Aparasu to Retrospective Studies
This is a "connection" page, showing publications Rajender Aparasu has written about Retrospective Studies.
Connection Strength
4.735
-
Comparative effectiveness of high-efficacy and moderate efficacy disease-modifying agents in reducing the annualized relapse rates among multiple sclerosis patients in the United States. Prev Med. 2025 Jan; 190:108180.
Score: 0.198
-
Infection Risk Associated with High-Efficacy Disease-Modifying Agents in Multiple Sclerosis: A Retrospective Cohort Study. Clin Pharmacol Ther. 2025 Feb; 117(2):561-569.
Score: 0.198
-
Factors associated with the initiation of high-efficacy disease-modifying agents over moderate-efficacy disease-modifying agents in multiple sclerosis. Mult Scler Relat Disord. 2024 Nov; 91:105896.
Score: 0.196
-
Association of oral disease-modifying agents and their adherence trajectories with annual relapses in multiple sclerosis. Mult Scler Relat Disord. 2024 May; 85:105539.
Score: 0.189
-
Cumulative Anticholinergic Burden and its Predictors among Older Adults with Alzheimer's Disease Initiating Cholinesterase Inhibitors. Drugs Aging. 2024 Apr; 41(4):339-355.
Score: 0.189
-
Real-world Comparative Effectiveness of Methotrexate-based Combinations for Rheumatoid Arthritis: A Retrospective Cohort Study. Clin Ther. 2023 09; 45(9):e177-e186.
Score: 0.181
-
Comparative adherence trajectories of oral disease-modifying agents in multiple sclerosis. Pharmacotherapy. 2023 06; 43(6):473-484.
Score: 0.179
-
Risk of Serious Adverse Events Associated With Individual Cholinesterase Inhibitors Use in Older Adults With Dementia: A Population-Based Cohort Study. Drugs Aging. 2022 06; 39(6):453-465.
Score: 0.167
-
FACTORS ASSOCIATED WITH SWITCHING FROM INJECTABLE TO ORAL DISEASE MODIFYING AGENTS AMONG PATIENTS WITH MULTIPLE SCLEROSIS. Mult Scler Relat Disord. 2022 Apr; 60:103703.
Score: 0.164
-
Risk of overactive bladder associated with cholinesterase inhibitors in dementia. J Am Geriatr Soc. 2022 03; 70(3):820-830.
Score: 0.161
-
Prescribing of disease modifying agents in older adults with multiple sclerosis. Mult Scler Relat Disord. 2022 Jan; 57:103308.
Score: 0.160
-
Antimuscarinic Cascade Across Individual Cholinesterase Inhibitors in Older Adults with Dementia. Drugs Aging. 2021 07; 38(7):593-602.
Score: 0.156
-
Antipsychotic Initiation Among Older Dementia Patients Using Cholinesterase Inhibitors: A National Retrospective Cohort Study. Drugs Aging. 2021 06; 38(6):493-502.
Score: 0.154
-
Comparative treatment effectiveness of oral fingolimod and conventional injectable disease-modifying agents in multiple sclerosis. Pharmacotherapy. 2021 05; 41(5):440-450.
Score: 0.154
-
Prevalence and Factors Associated with Cumulative Anticholinergic Burden Among Older Long-Stay Nursing Home Residents with Overactive Bladder. Drugs Aging. 2021 04; 38(4):311-326.
Score: 0.153
-
Comparative risk of adverse outcomes associated with nonselective and selective antimuscarinic medications in older adults with dementia and overactive bladder. Int J Geriatr Psychiatry. 2021 05; 36(5):684-696.
Score: 0.150
-
Higher Resource Utilization and Costs in Long-Term Nursing Home Residents With Overactive Bladder: A Retrospective Study of Medicare Beneficiaries. J Am Med Dir Assoc. 2021 06; 22(6):1300-1306.
Score: 0.149
-
Antimuscarinic Discontinuation in Patients with Overactive Bladder in Nursing Homes: A Retrospective Study of Medicare Beneficiaries. Adv Ther. 2020 08; 37(8):3584-3605.
Score: 0.146
-
Factors Associated with Prescribing Oral Disease Modifying Agents in Multiple Sclerosis: a Real-world Analysis of Electronic Medical Records. Mult Scler Relat Disord. 2020 Oct; 45:102334.
Score: 0.146
-
Marginal Health Care Expenditure Burden Among U.S. Civilian Noninstitutionalized Individuals with Multiple Sclerosis: 2010-2015. J Manag Care Spec Pharm. 2020 Jun; 26(6):741-749.
Score: 0.145
-
Risk of Mortality Associated With Atypical Antipsychotic use: A National Cohort Study of Older Adults With Depression and Parkinson's Disease. Am J Geriatr Psychiatry. 2020 10; 28(10):1079-1088.
Score: 0.142
-
Risk of Mortality Associated with Non-selective Antimuscarinic medications in Older Adults with Dementia: a Retrospective Study. J Gen Intern Med. 2020 07; 35(7):2084-2093.
Score: 0.142
-
Risk of Mortality in Elderly Nursing Home Patients with Depression Using Paroxetine. Pharmacotherapy. 2017 03; 37(3):287-296.
Score: 0.116
-
Discharge medication complexity and 30-day heart failure readmissions. Res Social Adm Pharm. 2017 Jul - Aug; 13(4):857-863.
Score: 0.113
-
Antimuscarinic Medication Use in Elderly Patients with Overactive Bladder. Drugs Aging. 2016 10; 33(10):755-763.
Score: 0.113
-
Comparative risk of hip fractures in elderly nursing home patients with depression using paroxetine and other selective serotonin reuptake inhibitors. J Comp Eff Res. 2016 08; 5(5):461-73.
Score: 0.111
-
Comparative Effectiveness of Second-Generation Antidepressants in Reducing the Risk of Dementia in Elderly Nursing Home Residents with Depression. Pharmacotherapy. 2016 Jan; 36(1):38-48.
Score: 0.107
-
Comparative Cognitive Profile of Second-Generation Antidepressants in Elderly Nursing Home Residents With Depression. Ann Pharmacother. 2016 Feb; 50(2):96-105.
Score: 0.106
-
Factors associated with the use of immune checkpoint inhibitors in older adults with metastatic non-small cell lung cancer and pre-existing autoimmune disease: A SEER-Medicare study. J Geriatr Oncol. 2024 11; 15(8):102071.
Score: 0.049
-
Pain-related hospitalization and emergency room visit following initial analgesic prescription after outpatient surgery. Pharmacoepidemiol Drug Saf. 2024 02; 33(2):e5759.
Score: 0.047
-
Adherence to Recommended Metabolic Monitoring of Children and Adolescents Taking Second-Generation Antipsychotics. Psychiatr Serv. 2024 Apr 01; 75(4):342-348.
Score: 0.046
-
Impact of the AACAP practice parameters on the metabolic adverse event monitoring for second-generation antipsychotics (SGAs) in children and adolescents. J Psychiatr Res. 2023 09; 165:170-173.
Score: 0.045
-
Impact of geographic access to primary care providers on pediatric behavioral health screening. Prev Med. 2021 12; 153:106856.
Score: 0.040
-
Racial/ethnic differences in treatment quality among youth with primary care provider-initiated versus mental health specialist-initiated care for major depressive disorders. Child Adolesc Ment Health. 2020 02; 25(1):28-35.
Score: 0.035
-
Reversibility of psychotropic medication induced weight gain among children and adolescents with bipolar disorders. Psychiatry Res. 2019 06; 276:151-159.
Score: 0.034
-
The concomitant use of tyrosine kinase inhibitors and proton pump inhibitors: Prevalence, predictors, and impact on survival and discontinuation of therapy in older adults with cancer. Cancer. 2019 04 01; 125(7):1155-1162.
Score: 0.033
-
Physician Care Coordination and the Use of Psychotropic Polypharmacy in the Management of Pediatric Mental Disorders. J Manag Care Spec Pharm. 2019 Jan; 25(1):29-38.
Score: 0.033
-
Outcomes associated with Clostridium difficile infection in patients with chronic liver disease. Epidemiol Infect. 2018 07; 146(9):1101-1105.
Score: 0.031
-
Effect of Psychopharmacotherapy on Body Mass Index Among Children and Adolescents with Bipolar Disorders. J Child Adolesc Psychopharmacol. 2017 May; 27(4):349-358.
Score: 0.029
-
Use of Angiotensin-Converting Enzyme Inhibitors, Angiotensin Receptor Blockers, and Risk of Dementia in Heart Failure. Am J Alzheimers Dis Other Demen. 2016 08; 31(5):395-404.
Score: 0.027